Hepatitis B Vaccine

Hepatitis B vaccine has been associated with severe, debilitating, and life threatening adverse reactions including: Polyneuropathy, Guillian-Barre’, Myasthenia Gravis, CNS demyelination, Transverse myelitis, Erythema nodosum, rheumatoid arthritis, colitis, autism, and more…45 different types of reactions reported to be in the world literature by researcher Dr. Andrea Valeri of Italy.

Vaccines: The Risks, the Benefits, the Choices, Dr. Sherri Tenpenny, 2nd Ed. (Video)

The two primary vaccines used for Hepatitis B in infants are ENERGIX-B and RECOMBIVAX HB.  The Hepatitis B vaccine is also included in PEDIARIX, which is a combination of DTaP, Hep B, and Polio vaccines.  This will be covered in the section on DTaP.

In January of 2009 the U.S. Federal Claims Court ruled that the Hepatitis B Vaccine caused Devic’s Disease (a variant of MS) which led to death.

U.S. Court of Federal Claims and Hep B Vaccine and Demyelinating Disease
http://www.uscfc.uscourts.gov/sites/default/files/MILLMAN.DOE012109B_0.pdf

Clustering of Cases of IDDM (diabetes) 2 to 4 Years after Hepatitis B Immunization
is Consistent with Clustering after Infections and Progression to IDDM in
Autoantibody Positive Individuals
http://www.vaccines.net/1TOPEDJ.pdf

The reason infants are vaccinated is availability.  The targeted population at risk had very poor compliance in getting the vaccination.

"Because vaccination limited to high-risk individuals has failed to substantially lower the
overall incidence of hepatitis B infection, both the Advisory Committee on Immunization Practices (ACIP) and the Committee on Infectious Diseases of the American Academy of Pediatrics (AAP) have also endorsed universal infant immunization as part of a comprehensive strategy for the control of hepatitis B infection."
                                                                 RECOMBIVAX Package Insert (see below)

Only those children exposed to infected mothers are at risk.  Antibody levels produced by vaccination will most likely decline to non-protective levels before children reach the age when they are sexually active or exposed to other risk factors.  Studies have shown that a majority of those vaccinated maintained adequate antibody levels for only 4-5 years.

                   The Vaccine Guide: Risks and Benefits for Children and Adults, Randall Neustaedter, OMD

CDC vaccine recommendation: Three doses at: Birth-2 mo., 1-4 mo., 6-18 mo.

The Hepatitis B Vaccine Information Statement (VIS) issued by the CDC.  This is the sheet given out by pediatricians.
http://www.immunize.org/vis/hepb01.pdf

This is an excellent 10-minute presentation on the Hepatitis B vaccine.
Think Twice Global Vaccine Institute: Hepatitis B Vaccine Powerpoint Presentation
http://thinktwice.com/hepB_sho.htm


 

RECOMBIVAX HB

RECOMBIVAX HB – Merck – Product Insert
http://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf

See p. 4 & 5 for adverse reactions

“The duration of the protective effect of RECOMBIVAX HB in healthy vaccinees is unknown at present, and the need for booster doses is not yet defined.” (Page 3)

RECOMBIVAX HB has not been evaluated for carcinogenic, or mutagenic potential, or for impairment of fertility.” –p.7

RECOMBIVAX HB contains yeast protein, soy peptone, dextrose, amino acids, mineral salts, potassium aluminum sulfate, amorphous aluminum hydroxyphosphate sulfate, formaldehyde, phosphate buffer
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf

 

ENGERIX-B

ENGERIX-B (Recombinant Vaccine) – GlaxoSmithKline – Package Insert
http://us.gsk.com/products/assets/us_engerixb.pdf

See p. 6-8 for adverse reactions

“ENGERIX-B has not been evaluated for carcinogenic, or mutagenic potential, or for impairment of fertility.” –p.11

In the safety studies cited in the previous version of this package insert, the placebo used in the studies of this vaccine were different types of vaccines. “Ten double-blind studies involving 2,252 subjects showed no significant difference in the frequency or severity of adverse experiences between ENGERIX-B and plasma-derived vaccines.”

So they simply found that there were no significant differences in adverse reactions between different vaccines, and therefore is considered “safe.” Also, subjects were only monitored for 4 days.

In this current package insert, 36 clinical studies are cited in which a total of 13,495 doses of ENGERIX-B were administered to 5,071 healthy adults and children.  As with previous safety studies, subjects were only monitored for 4 days.  No control group was cited.  Adverse reactions in these studies are listed on p.6-7.

ENGERIX-B contains aluminum hydroxide, phosphate buffers, yeast protein
http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf
 

 
© 2011 - • VaccineDecision.info